We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

43 hedge funds and large institutions have $111M invested in MoonLake Immunotherapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

0.21% more ownership

Funds ownership: 93.83% → 94.04% (+0.21%)

1% less capital invested

Capital invested by funds: $113M → $111M (-$1.65M)

7% less funds holding

Funds holding: 46 → 43 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
STALEY CAPITAL ADVISERS
Pennsylvania
+$798K
2
CAC
Cowen and Company
New York
+$623K
3
FC
Finepoint Capital
Massachusetts
+$323K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$170K
5
MWM
Meridian Wealth Management
Kentucky
+$151K

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$518K
2
MS
Maven Securities
Jersey
-$513K
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$330K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$323K
5
SCM
Silverarc Capital Management
Massachusetts
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$10.1M – – –
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$7.46M – – –
RI
3
RTW Investments
New York
$7.39M – – –
BlackRock
4
BlackRock
New York
$7.37M – – –
RCM
5
RA Capital Management
Massachusetts
$6.96M – – –
Citadel Advisors
6
Citadel Advisors
Florida
$6.77M -$57.8K -5,794 -0.8%
SCA
7
STALEY CAPITAL ADVISERS
Pennsylvania
$5.71M +$798K +80,000 +16%
GTC
8
Ghost Tree Capital
New York
$4.94M – – –
Wellington Management Group
9
Wellington Management Group
Massachusetts
$4.78M -$323K -32,409 -6%
CAM
10
Cormorant Asset Management
Massachusetts
$4.28M – – –
BC
11
Boxer Capital
California
$3.98M – – –
OCA
12
Octagon Capital Advisors
New York
$3.95M – – –
APM
13
Avidity Partners Management
Texas
$3.94M – – –
FC
14
Finepoint Capital
Massachusetts
$3.77M +$323K +32,400 +9%
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$3.18M – – –
ACM
16
Altium Capital Management
New York
$2.49M – – –
BCLSI
17
Bain Capital Life Sciences Investors
Massachusetts
$2.49M – – –
FCMV
18
Foresite Capital Management V
California
$2.49M – – –
TCM
19
Tekla Capital Management
Massachusetts
$2.47M – – –
SCM
20
Silverarc Capital Management
Massachusetts
$2.22M -$101K -10,114 -4%
EC
21
EcoR1 Capital
California
$1.99M – – –
RSCM
22
Rock Springs Capital Management
Maryland
$1.54M – – –
6CM
23
683 Capital Management
New York
$1.49M – – –
BCM
24
BlueCrest Capital Management
Jersey
$1.49M – – –
CCM
25
Consonance Capital Management
New York
$1.49M – – –
1
2

MLTX Hedge Fund Activity: Q3 2021 in Review

43 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2021, worth a combined $111M — down 1.5% from $113M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MLTX and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 8 added.

The largest buyer was STALEY CAPITAL ADVISERS, adding an estimated $798K. The largest seller was Logos Global Management, exiting entirely with an estimated $518K sold.

  • 43 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2021, down from 46 in Q2 2021.
  • Funds reported $111M of MoonLake Immunotherapeutics stock for Q3 2021, down 1.5% quarter-over-quarter.
  • 1 fund opened new MoonLake Immunotherapeutics positions in Q3 2021 and 4 closed out, a net change of -3 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q3 2021 was STALEY CAPITAL ADVISERS, an estimated $798K added.
  • The largest MoonLake Immunotherapeutics seller in Q3 2021 was Logos Global Management, an estimated $518K sold.

Based on aggregated 13F filings for Q3 2021.